Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A successful Phase 3 clinical trial of N-acetyl-leucine (NALL) in the lysosomal storage disorder Niemann-Pick disease type C has been published this month in the New England Journal of Medicine.

Following the successful trial, a new drug application (NDA) has been submitted to the Food and Drug Administration (FDA).

The study, sponsored by IntraBio, evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann–Pick disease type C. The trial found that, among patients with Niemann–Pick disease type C, treatment with NALL for 12 weeks led to better neurologic status than placebo. A longer period is needed to determine the long-term effects of this agent in patients with Niemann–Pick disease type C.

IntraBio is a spin out from Pharmacology co-founded by Antony Galione, Grant Churchill and Fran Platt. For the full paper, see

Similar stories

Collaboration in action - from a Pharmacology perspective

As part of the Medical Sciences Division's series on industry collaboration, Pharmacology's Associate Professor Sri Vasudevan shares the important of networking at conferences and listening to a range of views as vital building blocks that can lead to effective commercial partnerships.